Chimeric antigen receptor macrophages and methods of making same
By designing chimeric antigen receptors in macrophages, including co-stimulatory domains of Ncr1, TLR5, Rage, and Tim4, the signaling pathway mismatch problem of CAR-T/M technology in macrophages was solved, achieving high-efficiency expression of CAR-M cells and persistence and stability in the tumor microenvironment, thus enhancing the anti-tumor immune effect.
CN122103372APending Publication Date: 2026-05-29HAINAN UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HAINAN UNIV
- Filing Date
- 2026-03-09
- Publication Date
- 2026-05-29
Smart Images
Figure CN122103372A_ABST
Abstract
The application discloses a kind of chimeric antigen receptor macrophages and preparation method thereof.To the problem that traditional T cell costimulatory domain is not matched with macrophage signal pathway, the application provides a CAR structure specially designed for the biological characteristics of macrophage.The chimeric antigen receptor expressed by the CAR-M cell includes at least one costimulatory domain selected from Ncr1, TLR5, Rage and Tim4, and the CAR structure is composed of CD22 scFv extracellular antigen recognition region, CD8 alpha hinge region, transmembrane region, the costimulatory domain and CD3 zeta intracellular signal domain in sequence.By constructing the recombinant expression plasmid of pB vector skeleton and inserting P2A-EGFP expression monitoring element, RAW264.7 macrophages are transfected by using Zeta life transfection reagent, and the CAR positive rate can reach more than 97% by flow cytometry or confocal microscopy verification.The application realizes the efficient activation of phagocytosis, antigen presentation and microenvironment remodeling functions specific to macrophages, and significantly improves the application potential of CAR-M in solid tumor treatment.
Need to check novelty before this filing date? Find Prior Art